HARP News and Press, Harpoon Therapeutics Inc. From 12/08/23

2023-12-08 16:30:47 ET More on Harpoon Therapeutics Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch Biggest stock movers today: Chevron, EngageSmart, Crypto-focused stocks and more For further details see: Harpoon Therapeutics files to sell 25.75...

2023-11-27 13:24:37 ET Gainers: Redhill Biopharma Ltd. ( RDHL ) +198% . Biodexa Pharmaceuticals Plc ( BDRX ) +119% . Direct Digital Holdings ( DRCT ) +34% . Captivision ( CAPT ) +29% . MoneyHero Ltd ( MNY ) +28% . Beachbody C...

2023-11-27 10:50:10 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employ...

2023-11-24 09:46:18 ET More on Health Care Select Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment ...

2023-11-21 09:00:00 ET Summary HPN328 is being advanced in a phase 1/2 study for the treatment of patients with neuroendocrine tumors; Promising interim data was released at ESMO 2023 medical conference. Updated data from the phase 1/2 study, using HPN328 for the treatment of pati...

2023-11-10 10:46:28 ET More on Harpoon Therapeutics Biggest stock movers today: Chevron, EngageSmart, Crypto-focused stocks and more Harpoon climbs on data for cancer drug (updated) Seeking Alpha’s Quant Rating on Harpoon Therapeutics Historical earnin...

Harpoon Therapeutics Inc. (HARP) is expected to report $-3.09 for Q3 2023

October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung cancer (SCLC) and other neuroendocrine tumor types presented at ESMO 2023 HPN328 Phas...

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalat...

2023-10-23 13:20:00 ET Summary Chevron to buy Hess in an all-stock transaction for $53 billion. The 10-year Treasury yield briefly crosses 5% for the first time since 2007. Jefferies comes out with its USA Equity Strategy report and allocation recommendations. Listen...